CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...